|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.25 USD | +0.57% |
|
+5.24% | +74.04% |
| 09/04 | US CDC delays publishing report showing COVID vaccine benefits, WaPo reports | RE |
| 09/04 | US CDC delays publishing report showing Covid-19 vaccine benefits, Washington Post reports | RE |
Company Valuation: Moderna, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,02,976 | 69,006 | 37,919 | 16,001 | 11,523 | 20,210 | - | - |
| Change | - | -32.99% | -45.05% | -57.8% | -27.99% | 75.39% | - | - |
| Enterprise Value (EV) 1 | 92,848 | 59,104 | 29,315 | 8,976 | 5,724 | 16,345 | 17,766 | 18,163 |
| Change | - | -36.34% | -50.4% | -69.38% | -36.23% | 185.57% | 8.69% | 2.24% |
| P/E ratio | 8.98x | 8.93x | -8.07x | -4.48x | -4.06x | -7.15x | -11.2x | -17.8x |
| PBR | 7.24x | 3.7x | 2.74x | 1.46x | 1.33x | 3.19x | 4.31x | 5.58x |
| PEG | - | -0.3x | 0x | 0.2x | 0.2x | 3.86x | 0.3x | 0.5x |
| Capitalization / Revenue | 5.58x | 3.58x | 5.54x | 4.94x | 5.93x | 9.7x | 7.95x | 6.3x |
| EV / Revenue | 5.03x | 3.07x | 4.28x | 2.77x | 2.94x | 7.85x | 6.98x | 5.66x |
| EV / EBITDA | 6.86x | 6.05x | -8.1x | -2.39x | -2x | -5.98x | -10.1x | -19.4x |
| EV / EBIT | 6.98x | 6.27x | -6.92x | -2.28x | -1.86x | -5.67x | -9.01x | -15.2x |
| EV / FCF | 6.96x | 12.9x | -7.66x | -2.21x | -2.77x | -6.23x | -10.6x | -14.6x |
| FCF Yield | 14.4% | 7.75% | -13% | -45.2% | -36.1% | -16.1% | -9.44% | -6.85% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 | -7.125 | -4.548 | -2.855 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18,471 | 19,263 | 6,848 | 3,236 | 1,944 | 2,083 | 2,544 | 3,209 |
| EBITDA 1 | 13,528 | 9,768 | -3,618 | -3,756 | -2,859 | -2,731 | -1,764 | -938.2 |
| EBIT 1 | 13,296 | 9,420 | -4,239 | -3,945 | -3,074 | -2,881 | -1,972 | -1,196 |
| Net income 1 | 12,202 | 8,362 | -4,714 | -3,561 | -2,822 | -2,812 | -1,813 | -1,154 |
| Net Debt 1 | -10,128 | -9,902 | -8,604 | -7,025 | -5,799 | -3,865 | -2,444 | -2,047 |
| Reference price 2 | 253.98 | 179.62 | 99.45 | 41.58 | 29.49 | 50.96 | 50.96 | 50.96 |
| Nbr of stocks (in thousands) | 4,05,450 | 3,84,180 | 3,81,284 | 3,84,818 | 3,90,734 | 3,96,587 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | 14/02/25 | 13/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.15x | 7.85x | -5.98x | -.--% | 2.02TCr | |
| 19.07x | 4.38x | 13.03x | 0.52% | 7.68TCr | |
| 30.11x | 6.01x | 17.35x | 0.53% | 6.15TCr | |
| 38.26x | 12.88x | 23.58x | -.--% | 4.9TCr | |
| 33.43x | 3.56x | 10.28x | 2.99% | 4.73TCr | |
| 14.61x | 2.73x | 7.99x | -.--% | 2.54TCr | |
| 80.19x | 9.24x | 92.32x | -.--% | 1.96TCr | |
| 15.5x | 2.5x | 7.98x | -.--% | 1.91TCr | |
| 24.14x | 4.87x | 13.29x | -.--% | 1.52TCr | |
| -38.23x | 17.29x | -48.24x | -.--% | 1.45TCr | |
| Average | 20.99x | 7.13x | 13.16x | 0.4% | 3.49TCr | |
| Weighted average by Cap. | 24.90x | 6.56x | 15.08x | 0.61% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MRNA Stock
- Valuation Moderna, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition